Noël Thierry, François Fabienne, Paumard Patrick, Chastin Christiane, Brèthes Daniel, Villard Jean
Laboratoire des Sciences Végétales, Faculté de Pharmacie, Université René Descartes-Paris 5, Paris 75006, USA.
Antimicrob Agents Chemother. 2003 Apr;47(4):1275-84. doi: 10.1128/AAC.47.4.1275-1284.2003.
An unusual interaction between flucytosine and fluconazole was observed when a collection of 60 Candida lusitaniae clinical isolates was screened for cross-resistance. Among eight isolates resistant to flucytosine (MIC >/= 128 micro g/ml) and susceptible to fluconazole (0.5 < MIC < 2 micro g/ml), four became flucytosine-fluconazole cross resistant when both antifungals were used simultaneously. Fluconazole resistance occurred only in the presence of high flucytosine concentrations, and the higher the fluconazole concentration used, the greater the flucytosine concentration necessary to trigger the cross-resistance. When the flucytosine- and fluconazole-resistant cells were grown in the presence of fluconazole alone, the cells reversed to fluconazole susceptibility. Genetic analyses of the progeny from crosses between resistant and sensitive isolates showed that resistance to flucytosine was derived from a recessive mutation in a single gene, whereas cross-resistance to fluconazole seemed to vary like a quantitative trait. We further demonstrated that the four clinical isolates were susceptible to 5-fluorouracil and that cytosine deaminase activity was unaffected. Kinetic transport studies with [(14)C]flucytosine showed that flucytosine resistance was due to a defect in the purine-cytosine permease. Our hypothesis was that extracellular flucytosine would subsequently behave as a competitive inhibitor of fluconazole uptake transport. Finally, in vitro selection of spontaneous and induced mutants indicated that such a cross-resistance mechanism could also affect other Candida species, including C. albicans, C. tropicalis, and C. glabrata. This is the first report of a putative fluconazole uptake transporter in Candida species and of a possible resistance mechanism associated with a deficiency in the uptake of this drug.
在对60株葡萄牙念珠菌临床分离株进行交叉耐药性筛查时,观察到氟胞嘧啶与氟康唑之间存在一种不寻常的相互作用。在8株对氟胞嘧啶耐药(MIC≥128μg/ml)且对氟康唑敏感(0.5<MIC<2μg/ml)的分离株中,当同时使用这两种抗真菌药物时,有4株出现了氟胞嘧啶-氟康唑交叉耐药。氟康唑耐药仅在高浓度氟胞嘧啶存在时出现,且所用氟康唑浓度越高,引发交叉耐药所需的氟胞嘧啶浓度就越高。当氟胞嘧啶和氟康唑耐药细胞仅在氟康唑存在的情况下生长时,细胞恢复对氟康唑的敏感性。对耐药和敏感分离株杂交后代的遗传分析表明,对氟胞嘧啶的耐药性源于单个基因的隐性突变,而对氟康唑的交叉耐药性似乎表现为一种数量性状。我们进一步证明,这4株临床分离株对5-氟尿嘧啶敏感,且胞嘧啶脱氨酶活性未受影响。用[¹⁴C]氟胞嘧啶进行的动力学转运研究表明,氟胞嘧啶耐药是由于嘌呤-胞嘧啶通透酶存在缺陷。我们的假设是,细胞外氟胞嘧啶随后会作为氟康唑摄取转运的竞争性抑制剂。最后,对自发和诱导突变体的体外筛选表明,这种交叉耐药机制也可能影响其他念珠菌属物种,包括白色念珠菌、热带念珠菌和光滑念珠菌。这是关于念珠菌属中一种假定的氟康唑摄取转运体以及与该药物摄取缺陷相关的可能耐药机制首次报道。